Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

about

67 th annual meeting of the American Diabetes Association.Discontinued drug therapies to treat diabetes in 2015.

P2860

Q46961262-EDBC7A41-2887-4902-AF01-A71CA97999BC Q51327624-F1F15F1B-F603-4DA5-8C46-D0F9D56F9952

P2860

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

Item

http://www.wikidata.org/entity/Q38460231

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

@en

type

Item

label

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

@en

prefLabel

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

@en

P1476

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

@en

P2093

Jerry R Colca

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ

Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats

PPAR gamma and the treatment of insulin resistance.

Thiazolidinediones.

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Enhancing incretin action for the treatment of type 2 diabetes.

P304

1517-1523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.16.10.1517

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17922617

http://www.w3.org/2001/XMLSchema#string

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

about

P2860

P2860

Discontinued drugs in 2006: renal, endocrine and metabolic drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698